Exon-Skipping Therapy For DMD

Exon-Skipping Therapy For DMD

by | Sep 22, 2016 | RNA Therapeutics

The Science Behind Sarepta’s Hotly Debated Antisense Drug Sarepta’s (Cambridge, MA) Duchenne muscular dystrophy drug Exondys 51 crossed the finish line earlier this week, with a conditional stamp of approval by the FDA. This hotly debated regulatory result...